Product lifecycle solutions
We deliver intelligent insights through the pharmaceutical product lifecycle
From early-stage commercial opportunity assessment and market understanding, forecasting and landscaping, through ideation, concept testing, product and brand development, profiling, communications testing, launch and post-launch tracking, we can support pharma with intelligent market research and consulting solutions through the lifecycle of the brand.
Senior level involvement
Our large, senior team of over 40 Directors are involved at every stage of the project.
High quality research
Our outputs answer the key business questions with a clear, direct recommendation, supported by the research evidence.
Communication and flexibility
We keep clients informed through weekly updates and respond quickly to needs and deadlines.
A creative approach
We offer custom approaches, not branded solutions, so our research design is always creative and fresh.
- Some example case studiesHow we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
The challenge: Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful…read more »How we helped track and evaluate conference performance over time across multiple international events
Our client planned to have a significant presence at key global conferences over the course of a year. Find out how we effectively monitored perceptions of their brand across different regions over time.read more »How we used behavioural economic theory to reveal fresh insights into patient compliance
Our client currently has a product for a chronic rare disease which has seen an initial successful uptake. HCPs appear to support the product and are actively prescribing it to suitable patients.read more »
- Our latest white papersAre dual ARVs the new frontier in a maturing HIV market?
Tackling and managing HIV has been one of the pharmaceutical industry’s more distinguished achievements, despite the turbulence and antagonism that marked the early days of AIDS-related R&D and the industry’s relationships with governments, patients and activists.read more »Punching above your weight: Combining behavioural and attitudinal data to strengthen segmentations
In this paper we examine the differences between behavioural and attitudinal approaches to segmentation and outline how integration of the two can best be achieved to strengthen segmentation solutionsread more »